4-Chloro-5-sulfamoylanthranilic Acid structure
|
Common Name | 4-Chloro-5-sulfamoylanthranilic Acid | ||
|---|---|---|---|---|
| CAS Number | 3086-91-7 | Molecular Weight | 250.65900 | |
| Density | 1.726g/cm3 | Boiling Point | 549.2ºC at 760mmHg | |
| Molecular Formula | C7H7ClN2O4S | Melting Point | 267°C (dec.) (lit.) | |
| MSDS | N/A | Flash Point | 286ºC | |
| Symbol |
GHS07 |
Signal Word | Warning | |
| Name | 2-amino-4-chloro-5-sulfamoylbenzoic acid |
|---|---|
| Synonym | More Synonyms |
| Density | 1.726g/cm3 |
|---|---|
| Boiling Point | 549.2ºC at 760mmHg |
| Melting Point | 267°C (dec.) (lit.) |
| Molecular Formula | C7H7ClN2O4S |
| Molecular Weight | 250.65900 |
| Flash Point | 286ºC |
| Exact Mass | 249.98200 |
| PSA | 131.86000 |
| LogP | 2.63010 |
| Index of Refraction | 1.665 |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P305 + P351 + P338 |
| Hazard Codes | N |
| RIDADR | NONH for all modes of transport |
| HS Code | 2935009090 |
|
~51%
4-Chloro-5-sulf... CAS#:3086-91-7 |
| Literature: NITROMED, INC. Patent: WO2006/55542 A2, 2006 ; Location in patent: Page/Page column 69-70 ; WO 2006/055542 A2 |
|
~%
4-Chloro-5-sulf... CAS#:3086-91-7 |
| Literature: Journal of the American Chemical Society, , vol. 81, p. 5508 Journal of the American Chemical Society, , vol. 82, p. 2731,2733,2734 US2952680 , ; US2910488 , ; |
|
~%
4-Chloro-5-sulf... CAS#:3086-91-7 |
| Literature: Journal of the American Chemical Society, , vol. 81, p. 5508 Journal of the American Chemical Society, , vol. 82, p. 2731,2733,2734 US2952680 , ; US2910488 , ; |
|
~%
4-Chloro-5-sulf... CAS#:3086-91-7 |
| Literature: Journal of the American Chemical Society, , vol. 81, p. 5508 Journal of the American Chemical Society, , vol. 82, p. 2731,2733,2734 |
|
~29%
4-Chloro-5-sulf... CAS#:3086-91-7 |
| Literature: Tetrahedron, , vol. 67, # 49 p. 9518 - 9521 |
| HS Code | 2935009090 |
|---|---|
| Summary | 2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0% |
|
The use of HPLC to elucidate the metabolism and urinary excretion of furosemide and its metabolic products.
Acta Pharmacol. Toxicol. (Copenh.) 49(3) , 223-9, (1981) Three principles for the use of HPLC with spectrophotometric detection to determine the concentration of furosemide and of 4-chloro-5-sulfamoyl anthranilic acid (CSA) were studied. A reversed phase mi... |
|
|
The binding of furosemide to serum proteins in elderly patients: displacing effect of phenprocoumon.
Acta Pharmacol. Toxicol. (Copenh.) 47(3) , 202-7, (1980) The percentual binding of furosemide (5 micrograms/ml) was slightly but significantly lower in serum from elderly patients than in serum from normal blood donors (96.5 +/- 0.7 versus 97.9 +/- 0.3). A ... |
|
|
Furosemide accelerates gentamicin accumulation in cultured renal cells (LLC-PK1 cells).
Nephron 53(2) , 138-41, (1989) Furosemide is known to potentiate gentamicin nephrotoxicity. The mechanism of potentiation is unclear. In our previous studies, we demonstrated that furosemide enhanced gentamicin accumulation in rabb... |
| 4-Chloro-5-sulfamoylanthranilic acid |
| 2-AMINO-5-AMINOSULFONYL-4-CHLOROBENZOIC ACID |
| 4-chloro-5-sulphamoyl anthranilic acid |
| Desfurylmethylfurosemide |
| Saluamine |
| 2-amino-4-chloro-5-sulfamoyl-benzoic acid |
| Furosemide Related Compound B |
| EINECS 221-408-7 |
| 4-chloro-5-sulfamoyl-anthranilic acid |
| 4-Chloro-5-sulfanilanthranilic acid |